Casodex Non-Metastatic Prostate Cancer Use Needs More Study – FDA Cmte.
Executive Summary
AstraZeneca's Casodex needs longer-term follow-up data to support an indication for adjuvant therapy following surgery in non-metastatic prostate cancer, FDA's Oncologic Drugs Advisory Committee concluded Dec. 18
You may also be interested in...
AstraZeneca Casodex FDA Cmte. To Focus On Efficacy Differences In Trials
AstraZeneca expects FDA's Oncologic Drugs Advisory Committee's Casodex review to focus on the apparent lower efficacy of the prostate cancer drug in U.S. trials compared to those outside the U.S
AstraZeneca Casodex
SNDA withdrawn Dec. 19 for 150 mg bicalutamide for treatment of locally advanced, non-metastatic lung cancer. The company expects to refile in 2001
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011